Rogaratinib: Clinical Trials

7 trials of Rogaratinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed. 7 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 17Completed 7

Follow Rogaratinib: new trials by email Literature Review of Rogaratinib trials Research Report on Rogaratinib

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.
Combination, Rogaratinib + palbociclib + fulvestrant - Breast Cancer Metastatic, Hormone Receptor Positive Malignant Neoplasm of Breast
Phase 1CompletedFundacion CRIS de Investigación para Vencer el Cáncer92020-11-252023-12-28
Rogaratinib (BAY1163877) in Chinese Patients
Rogaratinib (BAY1163877) - Neoplasms
Phase 1CompletedBayer12019-01-072021-03-29
Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors
Rogaratinib (BAY1163877), Copanlisib (BAY80-6946) - Advanced or Metastatic Solid Tumor
Phase 1CompletedBayer162018-07-252022-07-14
Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma
Rogaratinib (BAY1163877), Atezolizumab - Urothelial Carcinoma
Phase 1CompletedBayer372018-05-152025-04-09
Rogaratinib (BAY1163877) Human Mass Balance Study
Rogaratinib (BAY1163877) - Clinical Trial, Phase I, Pharmacokinetics
Phase 1CompletedBayer62018-04-062018-08-14
Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors
BAY1163877 - Neoplasms
Phase 1CompletedBayer92015-12-152018-04-18
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
Rogaratinib (BAY1163877) oral solution, Rogaratinib (BAY1163877) oral tablet, Rogaratinib (BAY1163877) 800 mg BID - Neoplasms
Phase 1CompletedBayer1682013-12-302021-05-06

Conditions studied

Neoplasms (3)  ·  Neoplasm Metastasis (2)  ·  Urinary Bladder Neoplasms (2)  ·  Adenocarcinoma of Lung (1)  ·  Carcinoma, Transitional Cell (1)  ·  Head and Neck Neoplasms (1)

Sponsors

Bayer (6)  ·  Fundacion CRIS de Investigación para Vencer el Cáncer (1)

Countries

Spain (4)  ·  Germany (3)  ·  South Korea (3)  ·  United States (3)  ·  France (2)  ·  Japan (2)  ·  Singapore (2)  ·  Austria (1)  ·  Belgium (1)  ·  China (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Switzerland (1)

Top investigators

Luis Manso, MD (1)

Results publications

PMID 30807645, PMID 31405822, PMID 39298147

NIH funding

2017 (2), 2018 (1)